Top

Published in:

01-10-2006 | Original Article

Teriparatide’s effects on quantitative ultrasound parameters and bone density in women with established osteoporosis

Authors: S. Gonnelli, G. Martini, C. Caffarelli, S. Salvadori, A. Cadirni, A. Montagnani, R. Nuti

Published in: Osteoporosis International | Issue 10/2006

Abstract

This study aimed to evaluate the effects of teriparatide [hPTH (1–34)] on quantitative ultrasound (QUS) parameters and bone mineral density (BMD) at the axial and appendicular (hand) skeleton in women with established osteoporosis who had been previously treated with antiresorptive drugs. Sixty postmenopausal women (age 71.1±6.8 years) were randomly assigned to either receive once-daily 20-μg subcutaneous teriparatide (n=30) or continue the antiresorptive treatment (n=30). At baseline and at 2-month intervals we measured QUS parameters at the calcaneus using the Achilles Plus (GE, Lunar), measuring speed of sound (SOS), broadband ultrasound attenuation (BUA), and stiffness index; QUS parameters at the phalanxes using the Bone Profiler (IGEA), measuring amplitude-dependent speed of sound (AD-SoS), bone transmission time (BTT), and fast wave amplitude (FWA); and BMD values at the right hand using dual x-ray absorptiometry. BMD at the lumbar spine, femur, and whole body were measured on a 6-monthly basis. After 1 year of teriparatide treatment, the changes in BMD were 7.1% at the lumbar spine, 2.6% at the femoral neck, −0.8% at the total hip, and −0.6% for the whole body. Teriparatide induced a significant and persistent decrease in BMD at the hand (−3.6% at month 6 and −2.7% at month 12). In the teriparatide group at month 12, AD-SoS was slightly increased (0.7%; not significant), whereas BTT significantly decreased (−16.4%, p<0.001) and FWA significantly increased (17.5%, p<0.001). The FWA/BTT ratio increased by 26.6% and 32.9% at months 6 and 12, respectively, in the teriparatide group and remained unchanged in the antiresorptive group. In women with established osteoporosis who had previously been treated with various antiresorptive drugs, 1 year of teriparatide treatment determined the expected increase in BMD at the axial skeleton and a significant and prolonged decrease in BMD at the hand. Moreover, teriparatide determined important changes in BTT and FWA, two parameters obtained from the analysis of ultrasonographic trace at the phalanxes, which could be considered in monitoring for the early effect of teriparatide on bone.

Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570–578PubMedCrossRef

Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM (1994) Parathyroid hormone for prevention of bone loss induced by estrogen deficiency. N Engl J Med 331:1618–1623PubMedCrossRef

Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP (2000) Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069–3076PubMedCrossRef

Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perz A, Kaufman JM, Clancy AD, Gaich GA (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17PubMedCrossRef

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef

Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL (2003) Effects of teriparatide [recombinant human parathyroid hormone (134)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18:539–543PubMedCrossRef

Rehman Q, Lang TF, Arnaud CD, Modin GW, Lane NE (2003) Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 14:77–81PubMedCrossRef

Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM (2001) Intermittently administered human parathyroid hormone(134) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16:157–165PubMedCrossRef

Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R (2001) Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16:1846–1853PubMedCrossRef

10.

Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF (2003) Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932–1941

11.

Adami S, Viapiana G, Gatti D (2004) Bone anabolic agents: the unanswered queries. Basic Clin Pharmacol Toxicol 94:257–259

12.

Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on bMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745–751PubMedCrossRef

13.

Gluer CC, for the International Quantitative Ultrasound Consensus Group (1997) Quantitative ultrasound techniques for the assessment of osteoporosis: expert agreement on current status. J Bone Miner Res 12:1280–1288

14.

Njeh CF, Fuerst T, Diessel E, Genant HK (2001) Is quantitative ultrasound dependent on bone structure? A reflection. Osteoporos Int 12:1–15PubMed

15.

Hans D, Dargent-Molina P, Schott AM, Sebert JL, Cormier C, Kotzki PO, Delmas PD, Pouilles JM, Breart G, Meunier PJ, for the EPIDOS prospective study group (1996) Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet 348:511–514PubMedCrossRef

16.

Bauer DC, Gluer CC, Cauley JA, Vogt TM, Ensrud KE, Genant HK, Black DM, for the study of osteoporotic fractures research group (1997) Broadband ultrasound attenuation predicts fractures strongly and independently of densitometry in older women: a prospective study. Arch Intern Med 157:629–634PubMedCrossRef

17.

Mulleman D, Legroux-Gerot I, Duquesnoy B, Marchandise X, Delcambre B, Cortet B (2002) Quantitative ultrasound of bone in male osteoporosis. Osteoporos Int 13:388–393PubMedCrossRef

18.

Gonnelli S, Cepollaro C, Gennari L, Montagnani A, Caffarelli C, Merlotti D, Rossi S, Cadirni A, Nuti R (2005) Quantitative ultrasound and dual-energy X-ray absorptiometry in the prediction of fragility fracture in men. Osteoporos Int 16:963–968PubMedCrossRef

19.

Montagnani A, Gonnelli S, Cepollaro C, Bruni D, Franci MB, Lucani B, Gennari C (2002) Graphic trace analysis of quantitative ultrasound at phalanxes seems to improve the diagnosis of primary hyperparathyroidism among patients with low bone mass. Osteoporos Int 13:222–227PubMedCrossRef

20.

Krieg MA, Jacquet AF, Bremgartner M, Cuttelod S, Thieband D, Burckardt P (1999) Effect of supplementation with vitamin D3 and calcium on quantitative ultrasound of bone in elderly institutionalized women: a longitudinal study. Osteoporosis Int 9:483–488

21.

Gonnelli S, Cepollaro C, Montagnani A, Martini S, Gennari L, Mangeri M, Gennari C (2002) Heel ultrasonography in monitoring alendronate therapy: a four-year longitudinal study. Osteoporos Int 13:415–421PubMedCrossRef

22.

Wuster C, Albanese C, De Aloysio D, Duboeuf F, Gambacciani M, Gonnelli S, Gluer CC, Hans D, Joly J, Reginster JY, De Terlizzi F, Cadossi R (2000) Phalangeal osteosonogrammetry study: age-related changes, diagnostic sensitivity, and discrimination power. The Phalangeal Osteosonogrammetry Study Group. J Bone Miner Res 15:1603–1614

23.

Brownbill RA, Ilich JZ (2002) Validation of the use of the hand for estimating bone mineral density in other skeletal sites by DXA in healthy and osteoarthritic women. J Clin Densitom 5:273–282

24.

Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men whit osteoporosis. N Engl J Med 349:1216–1226PubMedCrossRef

25.

Cosman F, Nieves JW, Luckey MM, Zion M, Woelfert L, Lindsay R (2003) Daily versus cyclic PTH combined with alendronate versus alendronate alone for treatment of osteoporosis. J Bone Miner Res 18(Suppl 2):S32

26.

Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, Mc Clung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688–703PubMedCrossRef

27.

Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129–2134PubMedCrossRef

28.

Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R (2003) Efficacy and safety of human parathyroid hormone (1–84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88:5212–5220PubMedCrossRef

29.

Barkmann R, Lusse S, Stampa B, Sakata S, Heller M, Gluer CC (2000) Assessment of the geometry of human finger phalanges using quantitative ultrasound in vivo. Osteoporos Int 11:745–755PubMedCrossRef

30.

Sakata S, Barkmann R, Lochmuller EM, Heller M, Gluer CC (2004) Assessing bone status beyond BMD: evaluation of bone geometry and porosity by quantitative ultrasound of human finger phalanges. J Bone Miner Res 19:924–930PubMedCrossRef

31.

Ingle BM, Machado AB, Pereda CA, Eastell R (2005) Monitoring alendronate and estardiol therapy with quantitative ultrasound (QUS) and bone mineral density. J Clin Densitom 8:278–286PubMedCrossRef

32.

Hosokawa A, Otani T (1997) Ultrasonic wave propagation in bovine cancellous bone. J Acoust Soc Am 101:558–562PubMedCrossRef

33.

Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, Dempster DW, Nieves J, Shane E, Fratzl P, Klaushofer K, Bilezikian J, Lindsay R (2003) Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 88:1150–1156PubMedCrossRef

Title: Teriparatide’s effects on quantitative ultrasound parameters and bone density in women with established osteoporosis
Authors: S. Gonnelli
G. Martini
C. Caffarelli
S. Salvadori
A. Cadirni
A. Montagnani
R. Nuti
Publication date: 01-10-2006
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 10/2006
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-006-0157-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Teriparatide’s effects on quantitative ultrasound parameters and bone density in women with established osteoporosis

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2006

Radiographic texture analysis of densitometer-generated calcaneus images differentiates postmenopausal women with and without fractures

At what hip fracture risk is it cost-effective to treat?

Comparative study of axial and femoral bone mineral density and parameters of mandibular bone quality in patients receiving dental implants

Spinal cord injury causes more damage to bone mass, bone structure, biomechanical properties and bone metabolism than sciatic neurectomy in young rats

Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients

The 3D-based scaling index algorithm: a new structure measure to analyze trabecular bone architecture in high-resolution MR images in vivo